Oral Ivermectin for Chikungunya Viral Infection

Prince of Songkla University

Status and phase: Completed; Phase 3

Conditions: Clinical Syndrome

Treatments: Drug: Ivermectin

Study type: Interventional

Funder types: Other

Identifiers

NCT06259383

EC:55-141-14-1-3/sub1

Details and patient eligibility

About

Chikungunya viral infection (CVI) is a mosquito-borne infection, caused by chikungunya virus (CHIKV), an alphavirus, belonging to the family Togaviridae. This infection causes febrile illness associated with high fever, rash, acute deliberating and persistent arthralgia. There is no licensed vaccine or specific treatment for this infection. Ivermectin (IVM), commonly-used antiparasitic, has been demonstrated to inhibit replication of CHIKV.

Enrollment: 120 patients

Sex: All

Ages: 18 to 80 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• patients with virologic confirmation of chikungunya infection who had symptoms less than 72 hours prior to visit

Exclusion criteria

• patients with virologic confirmation of chikungunya infection who had symptoms more than 72 hours prior to visit

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

120 participants in 2 patient groups

Patients received oral ivermectin, adjunctive to conventional treatment

Experimental group

Treatment:

Drug: Ivermectin

Patients received conventional treatment

No Intervention group